Drug Profile
IMA 910
Alternative Names: Colorectal cancer vaccine - Immatics N.V.; IMA910Latest Information Update: 07 Jul 2020
Price :
$50
*
At a glance
- Originator immatics biotechnologies GmbH
- Class Cancer vaccines; Peptide vaccines; Peptides
- Mechanism of Action T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Colorectal cancer
Highest Development Phases
- No development reported Colorectal cancer
Most Recent Events
- 01 Jul 2020 Immatics N.V and Immatics Biotechnologies GmbH combined to form Immatics N.V.
- 29 Sep 2015 No recent reports on development identified - Phase-I/II for Colorectal cancer (Combination therapy, Late-stage disease, Treatment-experienced) in Belgium, Bulgaria, Germany, Hungary, Latvia, Poland, Romania, Serbia and United Kingdom (Intradermal)
- 24 Jan 2012 Efficacy and adverse events data from a phase I/II trial in Colorectal cancer (treatment-experienced patients, combination therapy, late-stage disease) released by immatics biotechnologies